Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Clinical Immunology
Published in: Journal of Clinical Immunology 3/2021

01-04-2021 | Glucocorticoid | Letter to Editor

Benralizumab in Severe and Refractory PDGFRA-Negative Hypereosinophilic Syndrome

Authors: Iolanda Alen Coutinho, Frederico S. Regateiro, Carlos Loureiro, Ana Todo-Bom

Published in: Journal of Clinical Immunology | Issue 3/2021

Login to get access

Excerpt

Hypereosinophilic syndrome (HES) is a rare, heterogeneous group of disorders characterized by persistent, marked blood eosinophilia associated with eosinophil-induced tissue/organ damage, causing a wide range of clinical manifestations [1]. Treatment includes glucocorticoids, immunosuppressors, and cytotoxic agents [1]. A highly variable response to treatment reflects the heterogeneity of the syndrome, and some patients are resistant to glucocorticoid treatment [1]. …
Literature
1.
2.
Kuang FL, Legrand F, Makiya M, Ware J, Wetzler L, Brown T, et al. Benralizumab for PDGFRA-negative hypereosinophilic syndrome. N Engl J Med. 2019;380(14):1336–46.CrossRef
3.
Forero Molina MA, Coffey KE, Chong HJ. Successful treatment of idiopathic hypereosinophilic syndrome with benralizumab in a pediatric patient. J Allergy Clin Immunol Pract. 2020;S2213–2198(20):30866–7.
4.
Bruscky DMV, Melo ACCDB, Sarinho ESC. Cross-cultural adaptation and validation of the itching severity scale in children and adolescents with atopic dermatitis. adaptação transcultural e validação da escala de gravidade de prurido em crianças e adolescentes com dermatite atópica. Rev Paul Pediatr. 2017;35(3):244–51.CrossRef
5.
Pais-Ribeiro J, Silva I, Ferreira T, Martins A, Meneses R, Baltar M. Validation study of a Portuguese version of the Hospital Anxiety and Depression Scale. Psychol Health Med. 2007;12(2):225–37.CrossRef
6.
Finlay AY, Khan GK. Dermatology life quality index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210–6.CrossRef
Metadata
Title
Benralizumab in Severe and Refractory PDGFRA-Negative Hypereosinophilic Syndrome
Authors
Iolanda Alen Coutinho
Frederico S. Regateiro
Carlos Loureiro
Ana Todo-Bom
Publication date
01-04-2021
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue 3/2021
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-020-00946-9

Other articles of this Issue 3/2021

Journal of Clinical Immunology 3/2021 Go to the issue

Original Article

Liver Abscess in Chronic Granulomatous Disease—Two Decades of Experience from a Tertiary Care Centre in North-West India

Letter to Editor

Clinical and Immunological Analyses of Ten Patients with MIRAGE Syndrome

CME Review

STING-Mediated Lung Inflammation and Beyond

Original Article

Inherited GATA2 Deficiency Is Dominant by Haploinsufficiency and Displays Incomplete Clinical Penetrance

Original Article

Differential Expression of Interferon-Alpha Protein Provides Clues to Tissue Specificity Across Type I Interferonopathies

Original Article

An Unusual Pattern of Premature Cervical Spine Degeneration in STAT3-LOF
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits